<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800822</url>
  </required_header>
  <id_info>
    <org_study_id>C4481001</org_study_id>
    <nct_id>NCT04800822</nct_id>
  </id_info>
  <brief_title>PF-07284892 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PF-07284892 (ARRY-558) as a Single Agent and in Combination Therapy in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-patient, open label study is to determine the maximum tolerated&#xD;
      dose and/or recommended dose for further study of PF-07284892 as a single agent and in&#xD;
      combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the&#xD;
      pharmacokinetics, safety, and preliminary clinical activity of single agent and each&#xD;
      combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 days)</time_frame>
    <description>DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with lorlatinib, encorafenib + cetuximab, or binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2- Number of participants with treatment-emergent adverse events (AEs)</measure>
    <time_frame>Baseline up to 30 days after last dose of study medication</time_frame>
    <description>AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2 - Number of participants with clinically significant change from baseline in laboratory abnormalities</measure>
    <time_frame>Baseline up to 30 days after last dose of study treatment</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2 - Number of dose interruptions, dose modifications, and discontinuations due to AEs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study medication</time_frame>
    <description>Incidence of dose interruptions, dose modifications, and discontinuations due to AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3- Overall response</measure>
    <time_frame>Baseline to up to 2 years</time_frame>
    <description>Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Maximum plasma concentration (Cmax) of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; end of treatment (EOT)</time_frame>
    <description>single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Time to reach maximum plasma concentration (Tmax) of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT</time_frame>
    <description>Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT</time_frame>
    <description>Single dose PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUCinf) of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT</time_frame>
    <description>Single dose and multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Metabolite ratio of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT</time_frame>
    <description>Single dose PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Area under the plasma concentration-time curve from 0 to 24 (AUC24) or 48 hours (AUC48) of PF-07284892 and metabolite</measure>
    <time_frame>Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8 hours postdose); Cycle 1 Day 18 (predose, 1, 2, 4, 6, 8, 24, and 48 hours postdose); Cycle 2-6 Day 1 (predose and 2 hours postdose); Cycle 7-12 Day 1 predose; EOT</time_frame>
    <description>Multiple dose (assuming steady state is achieved) PK parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2- Overall response</measure>
    <time_frame>Baseline to up to 2 years</time_frame>
    <description>Response will be evaluated via radiographical tumor assessments by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2- Duration of Response (DOR)</measure>
    <time_frame>Baseline to up to 2 years</time_frame>
    <description>Time from the first documentation of objective response to the first documentation of objective progressive disease, relapse or to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">211</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>PF-07284892 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07284892 in combination with lorlatinib (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib without prior platinum-based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib with prior platinum-based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC resistant to BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC refractory to BRAFi plus EGFRi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07284892 in combination with encorafenib and cetuximab (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-07284892 in combination with binimetinib (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07284892</intervention_name>
    <description>PF-07284892</description>
    <arm_group_label>Expansion Phase (Cohort 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 2)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 3)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 4)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 5)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 6)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 7)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with binimetinib (Part 2)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with encorafenib and cetuximab (Part 2)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with lorlatinib (Part 2)</arm_group_label>
    <arm_group_label>PF-07284892 monotherapy</arm_group_label>
    <other_name>ARRY-558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorlatinib</intervention_name>
    <description>lorlatinib</description>
    <arm_group_label>Expansion Phase (Cohort 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 2)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 3)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with lorlatinib (Part 2)</arm_group_label>
    <other_name>Lorbrena; PF-06463922, Lorviqua</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>binimetinib</description>
    <arm_group_label>Expansion Phase (Cohort 7)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with binimetinib (Part 2)</arm_group_label>
    <other_name>Mektovi, PF-06811462, MEK162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>cetuximab</description>
    <arm_group_label>Expansion Phase (Cohort 4)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 5)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 6)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with encorafenib and cetuximab (Part 2)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>encorafenib</description>
    <arm_group_label>Expansion Phase (Cohort 4)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 5)</arm_group_label>
    <arm_group_label>Expansion Phase (Cohort 6)</arm_group_label>
    <arm_group_label>PF-07284892 in combination with encorafenib and cetuximab (Part 2)</arm_group_label>
    <other_name>Braftovi, PF-07263896, LGX818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years at the time of informed consent&#xD;
&#xD;
          -  Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF&#xD;
             V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor.&#xD;
             Participants with ROS-positive NSCLC are also eligible for Part 1 and 2&#xD;
&#xD;
          -  Documentation evidence of biomarker mutation status&#xD;
&#xD;
          -  Part 3:&#xD;
&#xD;
        ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort&#xD;
        1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no&#xD;
        prior lorlatinib (Cohort 3).&#xD;
&#xD;
        BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to&#xD;
        BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6).&#xD;
&#xD;
        RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC&#xD;
        (Cohort 7).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis larger than 4 cm&#xD;
&#xD;
          -  Active malignancy within 3 years&#xD;
&#xD;
          -  Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to&#xD;
             start of study treatment. Antibody based agents within 4 weeks prior to start of study&#xD;
             treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study&#xD;
             treatment.&#xD;
&#xD;
          -  For participants who may get lorlatinib or encorafenib on study, history of&#xD;
             interstitial lung disease&#xD;
&#xD;
          -  For participants who may get binimetinib on study, history or current evidence of&#xD;
             retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with&#xD;
             elevated creatine kinase (CK)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Pharmacy)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4481001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>B-type Raf proto-oncogene (BRAF) mutation</keyword>
  <keyword>Ras mutation</keyword>
  <keyword>anaplastic lymphoma kinase (ALK)-positive</keyword>
  <keyword>neurofibromatosis type 1 (NF1)</keyword>
  <keyword>ROS1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

